iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
January 9, 2025
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
